Friday, 03 Apr 2020

You are here

Steroids Use in Lupus Linked to Damage Accural

A report from Lancet Rheumatology shows that glucocorticoid use contributes to damage accrual in systemic lupus erythematosus (SLE) independent of disease activity.

The authors undertook this study to evaluate the effects of steroid use in SLE, as it often confounds analyses of activity and damage.

This multinational study enrolled adult SLE patients and followed their disease activity measures (by SLEDAI-2K and Physician Global Assessment [PGA] scores), drug use and organ damage (according to the Systemic Lupus International Collaborating Clinics Damage Index - SDI).

A total of 1707 patients were recruited between 2013-17 and followed for a median of 2·2 years. Organ damage accrual events were observed in 255 (15%) patients. Over 82% of patients were exposed to prednisolone.

Factors independently associated with damage accrual included time-adjusted mean prednisolone dose, age at enrolment, and ethnicity (Asian vs non-Asians).

In the overall cohort, glucocorticoid use was independently associated with accrual of irreversible organ damage, measured by Systemic Lupus International Collaborating Clinics Damage Index (SDI), after adjusting for measurable disease activity.

In this study irreversible organ damage was accrued at a similar rate in the subset of patients with inactive disease as in the cohort as a whole. Around two-thirds of patients with inactive disease were exposed to glucocorticoids, and glucocorticoid use was independently associated with organ damage in these patients.

These data underscore the harmful effects of glucocorticoids in SLE. Minimizing steroid use in active SLE remains a challenge and may be dependent on the development of new, effective SLE treatment strategies.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

In Lupus, Keep BP Below 130/80

Blood pressure should be maintained at a level below 130/80 mm Hg in all patients with lupus to lessen their likelihood of atherosclerotic vascular events, Canadian researchers asserted.

In Vasculitis, Beware of Infection

Risks of infection were strikingly high among patients with antineutrophil cytoplasmic antibody-associated (ANCA) vasculitis, which may relate to both the disease and its treatment, Scottish researchers found.

Malignancies with Giant Cell Arteritis

The Journal of Rheumatology reports the findings of a Swedish population-based cohort study of biopsy-proven giant cell arteritis (GCA) patients showing that the overall risk for cancer was not increased; yet there appears to be an increased risk for leukemia and a decreased risk for breast and upper gastrointestinal tract cancers.   

Hospitalized GPA - Higher morbidity, Mortality and Cost

Rheumatology reports on a study of patients with granulomatosis with polyangiitis (GPA) showing worse outcomes and higher costs when hospitalized with GPA.

GPA patients were identified from the Nationwide Inpatient Sample (NIS) and were compared to those without GPA with regard to demographics, procedures, length of stay, mortality, morbidity and total hospitalization charges (between 2005–2014).

Don't Blame the Weather in Sjogren's

Seasonal variations in symptoms -- commonly reported by patients with rheumatic diseases -- were not observed in a large cohort of patients with primary Sjogren's syndrome, French investigators found.